34 results about "Vaccine virus" patented technology

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

To disclose modified influenza virus neuraminidases that improve viral replication, thus improving the yield of vaccine viruses.SOLUTION: Expression of such modified neuraminidases by influenza virus stabilizes co-expressed hemagglutinins, ensuring that the hemagglutinins do not undergo mutation or decrease the need for HA binding to cells.SELECTED DRAWING: None

A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.

The invention relates to the fields of molecular biology and virology, and provides a method for preparing a specific MHC haplotype-derived cell-binding virus. The method comprises the following steps: firstly, obtaining chick embryos of different haplotypes, separating CEF cells, transiently expressing exogenous fluorescent protein through electrotransfection, then carrying out virus inoculation, carrying out flow sorting to obtain a fluorescent positive cell population carrying MDV, and carrying out quantitative analysis on the cell population to obtain the specific MHC haplotype chicken Marek's Disease Virus (MDV), thereby obtaining the specific MHC haplotype chicken Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus. And carrying out in-vitro propagation to obtain the purified MDV with a specific haplotype source. The purified virus can provide a test material for related research of haplotype on virus infection, and can be widely applied to in-vitro purification of different cell binding viruses and related research of specific MHC molecule presenting virus peptides. The method disclosed by the invention is beneficial to carrying out related research aiming at the host immune response of the virus and analyzing the hereditary basis of haplotype to MDV differential resistance, and is expected to be applied to preparation of vaccine virus.

The invention discloses a bovine virus diarrhea live vaccine based on suspension culture and a preparation method thereof, and relates to the field of animal vaccines. The bovine viral diarrhea virus vaccine is a freeze-dried vaccine, and each vaccine contains a bovine viral diarrhea virus BVDV attenuated strain antigen and a freeze-drying protective agent; wherein the virus content of the antigen of the BVDV attenuated strain is 105-107 CCID50 / piece, and the BVDV attenuated strain is a cytopathic effect type attenuated strain suitable for suspension culture; the freeze-drying protective agent comprises trehalose, cane sugar, gelatin hydrolysate, sodium glutamate and polyvinylpyrrolidone. The suspension culture technology is adopted, large-scale, efficient and stable production of BVDV antigens is achieved, an optimized freeze-drying formula is combined, the obtained vaccine is high in virus titer, good in immunogenicity, high in stability, good in safety, advanced in production process, controllable in cost and suitable for industrial large-scale production.

The present invention relates to: a virus production method comprising a step for mixing a virus-infected cell and a non-infected cell and co-culturing the same to proliferate a virus; a virus strain for vaccination characterized by having 0.6 times or more of the expression level of the membrane surface glycoprotein gp51 as compared with the expression level of the capsid protein p24; and a vaccine composition characterized by comprising the vaccine virus strain that has been inactivated.

This disclosure provides compositions and methods for treating and / or preventing monkeypox infection and / or symptoms post-infection, the method including administering a composition including at least one attenuated vaccinia virus, the at least one attenuated vaccinia virus including a modification to the coding sequence of E3L.

The present invention relates to an oncolytic vaccinia virus and viral vectors for use in the treatment of cancer wherein the virus consists of at least three vaccinia virus promoters positioned in the same orientation.

The invention discloses a method for preparing a virus solution of a live attenuated varicella vaccine, comprising the following steps: preparing a mixed culture medium, passage human diploid cells, inoculating the cells with the varicella zoster virus Oka strain and performing primary and secondary culture, harvesting the virus multiple times, and finally freezing the virus harvest solution; the culture solution of the human diploid cell passage and the cells after virus inoculation are both composed of a mixed culture medium and bovine serum. The invention is based on a mixed culture medium combined with secondary culture and multiple virus harvesting methods, which can greatly improve the virus yield and cell utilization rate and save the cost of passaged cells.

The invention relates to an infectious spleen and kidney necrosis virus recombinant adenovirus oral preparation which is characterized by comprising the following components in percentage by mass: 2-4% of bovine serum albumin, 3-7% of lactose, 1-3% of glycine, 1-3% of mannitol, 2-4% of povidone, 1-2% of talcum powder and 0.8-3% of magnesium stearate. The balance is the cultured infectious spleen and kidney necrosis virus recombinant adenovirus liquid. The infectious spleen and kidney necrosis virus recombinant adenovirus strain is used as a vaccine virus, a wrapping agent, a protective agent and the like are added and mixed, the mixture can be added into a conventional feed, vaccine oral inoculation is achieved, the immune effect is equivalent to vaccine injection inoculation, and the vaccine has the advantages of being convenient to use, saving labor cost, reducing fish body stress loss and the like. The oral preparation disclosed by the invention is good in stability, the loss rate of active substances is low within the period of validity, and the disintegration time limit accords with national regulations.

A reared colony of larval superworms (Zophobas morio) experienced the swift and unexplained death of about 90% of its population. From dead larvae, a high-abundance virus was isolated and identified as a novel densovirus, Zophobas morio black wasting virus (ZmBWV), by means of cryo-electron microscopy. Strains of this virus were sequenced and an engineered vaccine virus sequence was developed. The black wasting disease was replicated in larvae by inoculation with pathogenic strains of ZmBWV. Larvae were inoculated with a non-pathogenic strain as prophylaxis and later challenged by inoculation with a pathogenic strain. The larvae that received a non-pathogenic strain were protected from later disease and death but the larvae that received a saline solution were not. The invention provides methods and vaccine products to inhibit morbidity and mortality of ZmBWWV in darkling beetle larvae.

This invention discloses PCR primers and probes for detecting ILT live vaccine virus and wild-type virus. The primers include a universal upstream primer: 5'-GCACAAAGTCCAAATCTTCT-3' and a universal downstream primer: 5'-TCAATCACAGACGGTACTTTC-3'. The probes include a vaccine virus-specific probe: 5'-FAM-CAAGTTGATGAATATGCTCAC-MGB-3' and a wild-type virus-specific probe: 5'-ROX-CAAGTTGATGAATGTGCTCA-MGB-3'. The 5' end of the vaccine virus probe is labeled with the FAM fluorescent group, and the 5' end of the wild-type virus probe is labeled with the ROX fluorescent group. The 3' ends of both probes are labeled with the MGB quencher group. Using these primers and probes, ILT live vaccine virus and wild-type virus can be detected and distinguished rapidly and accurately, and can be used for epidemic monitoring in farms.

The invention discloses a CAV-VP1-P2A-VP2 recombinant adenovirus vector live vaccine and application of the CAV-VP1-P2A-VP2 recombinant adenovirus vector live vaccine, and belongs to the technical field of vaccines. According to the characteristics of a natural protective antigen of the chicken anemia virus, fragments beneficial to vaccine preparation are artificially screened, after 305aa-320aa and 78aa-84aa regions with low KU645520.1 protein antigenicity are deleted, a GGGGS connecting arm is used for connection to obtain the VP1-VP2 recombinant protein, and the VP1-VP2 recombinant protein only retains a high-antigenicity core region, can be more efficiently recognized by an immune system, and has a good application prospect. The immune response intensity is enhanced; and the cross-host characteristic of the shuttle plasmid is adapted. The virus titer level of the recombinant adenovirus vector live vaccine obtained on the basis is greater than or equal to 4.74 * 10 < 10 > pfu / mL, and the immune effect on the chicken anemia virus is outstanding.

The application provides a feline calicivirus LZ-2016 strain and a vaccine composition. The feline calicivirus LZ-2016 strain has a high virus titer, the strain has strong pathogenicity to cats, and can cause typical symptoms such as oral ulcer and conjunctivitis. The inactivated product of the strain can produce a good immune response when cats are immunized, has good immunogenicity, can better stimulate the body to produce high-level neutralizing antibodies against FCV, can provide high immunoprotection rate to FCV attack, and has basic potential for developing a vaccine. The strain can be prepared into a vaccine and used for feline calicivirus prevention and treatment, provides an important vaccine virus source for feline calicivirus prevention and control in China, and realizes effective feline calicivirus prevention and control.

The present invention provides genetically modified vaccinia virus which may be employed as an oncolytic viral vector, wherein the genetically modified vaccinia virus comprises a nucleic acid molecule encoding a modified matrix protein from a vesicular stomatitis virus and wherein the genetically modified vaccinia virus is fusogenic.

The present invention relates to a primer set capable of differentiating a field strain of African swine fever virus from a live vaccine virus, and a use thereof and, more specifically, to: 13 types of primer sets for conventional PCR and 12 types of primer sets for qRT-PCR capable of differentiating a field strain of African swine fever virus from a live vaccine virus; a kit for differentiating a field strain from a vaccine strain of African swine fever virus, comprising the primer sets; and a method for differentiating suids infected with a field strain of African swine fever virus from suids inoculated with a vaccine strain, using the primer sets.

Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation.

A method of predicting preferred candidate viral strains for vaccine production is described herein. A machine learning framework for predicting preferred candidate viral strains is provided that emphasizes antigen-matching and yield predictions that correlate with features of viral proteins.

Provided herein are isolated, non-naturally occurring, broadly reactive antigens derived from H3 (H3N2) influenza virus that are immunogenic and are capable of eliciting a broadly reactive immune response, such as a broadly reactive neutralizing antibody response, against H3 (H3N2) viruses following introduction into a subject. Also provided are non-naturally, broadly reactive occurring immunogens, vaccines, virus-like particles (VLPs) and compositions comprising the immunogens and vaccines. Methods of generating an immune response in a subject by administering the isolated immunogens, vaccines, VLPs, or compositions thereof are provided. In particular, the immunogens are recombinant and comprise the hemagglutinin (HA) protein of the H3 (H3N2) influenza virus strain.

The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.

The present invention relates to a modified live porcine reproductive and respiratory syndrome virus. The virus is genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The ability of the modified live virus to provide protective immunity against heterologous viruses is evaluated. The modified live virus can be used in a vaccine, particularly a vaccine that can treat infections in pigs caused by a variety of heterologous viruses.

The invention discloses a Marek's low virulent strain, the whole genome sequence of the Marek's low virulent strain is characterized in that a nucleotide sequence as shown in SEQ ID NO.1 is deleted behind the 123439th basic group of a Marek's virus gene sequence DQ530348.1, and a long terminal repetitive sequence of avian reticuloendotheliosis virus as shown in SEQ ID NO.2 is inserted behind the 123439th basic group. The invention also discloses a construction method of the Marek's low virulent strain rescue system and application of the Marek's low virulent strain in preparation of vaccines for preventing or treating Marek's disease. The Marek's attenuated strain disclosed by the invention can quickly generate antibodies, has the detoxification capability obviously weaker than that of a vaccine virus CVI988 / Rispens strain, is a high-quality vaccine strain for developing Marek's disease vaccines, and has a very good application prospect.

An isolated infectious bronchitis (IB) virus (IBV) QX1285 strain under accession number DPS RE RSCIC 41 in the IZSLER biobank. A vaccine comprising the isolated infectious bronchitis virus and a carrier. The virus may be inactivated. The virus may alternatively be live and attenuated. The vaccine may be formulated for an avian. The avian may be a chicken. The vaccine may be administrated via drinking water. Also claimed is an isolated infectious bronchitis virus having an S1 protein encoded by SEQ ID NO: 1 or a sequence having at least 96% sequence identity thereto, for use as a vaccine against infectious bronchitis. Also claimed is a method of vaccinating an avian against infectious bronchitis, comprising administering the vaccine. Also claimed is a process for preparing a live infectious bronchitis vaccine comprising passaging the virus to reduce pathogenicity, harvesting the attenuated virus, and processing the virus to produce a vaccine. The virus may be passaged at least 50 times. The virus may be passaged by culturing in allantoic fluid of chicken embryos.

Modified influenza virus neuraminidases are described herein that have stabilized NA tetramers which may improve vaccine production efficiency, thus improving the yield of vaccine viruses.

The invention refers to new immuno-modulated replication-efficient Vaccinia virus strain (IOVA) and its derivatives for the use in medicine.

The invention relates to the field of virology. In particular, the invention relates to a polypeptide for quantitatively detecting the HA protein of H5N1, a kit containing the polypeptide, and a method for quantitatively detecting the HA protein of H5N1 by using the polypeptide. The method is a quantitative method with high throughput, high selectivity and high sensitivity, and can be used for absolute quantification of HA protein in H5N1 vaccine virus liquid.

The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.

The present disclosure relates to sVERO 7C2, which is a Vero cell line derived from Vero cells (African Green Monkey Kidney Cell Line) distributed from the WHO and capable of suspension culture without serum components. Further, the present disclosure relates to a culture method for growing the Vero cells and a method for producing a vaccine virus using the Vero cells.

The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.

The application discloses a PCR primer and probe for identifying serum type I Marek's vaccine virus and wild virus, wherein the primer comprises an upstream primer with a sequence as shown in SEQ ID No:1 and a downstream primer with a sequence as shown in SEQ ID No:2; and the probe comprises a wild virus-specific probe with a sequence as shown in SEQ ID No:3 and a vaccine virus-specific probe with a sequence as shown in SEQ ID No:4. Through the primer and the probe, the serum type I Marek's vaccine virus and the wild virus can be efficiently, conveniently and quickly identified, so that early warning, accurate prevention and control and purification of Marek's disease are realized.